Tetra Bio-Pharma Signs a Definitive Distribution Agreement with DanCann Pharma to Monetize Its Dronabinol and Botanical Product Portfolios
ACCESSWIRE
This Definitive Agreement is expected to generate an excess of $
47,5M CAD
), a leader in cannabinoid-derived drug discovery and development announced today the signing of a Definitive Agreement with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany.
Subject to registration with the European Medicines Agency (EMA), DanCann Pharma will handle the exclusive sales and distribution in the Nordics and Germany for Reduvo™ Adversa® and QIXLEEF™, a botanical cannabinoid-derived medicine, as well as Tetra s medicinal cannabis product ENJOUCA™.
Vancouver, British Columbia (Newsfile Corp. - May 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (
NervGen the
Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announced that it has launched an overnight, best efforts marketed public offering (the
Offering ) of units (the
Units ), each Unit being comprised of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, a
Warrant ). The number of Units to be distributed under the Offering, the price of each Unit and the exercise price of each Warrant will be determined in the context of the market.
Urogen Pharma (URGN) Receives a Buy from H C Wainwright analystratings.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from analystratings.com Daily Mail and Mail on Sunday newspapers.
Markets
Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Urogen Pharma (URGN – Research Report) today. The company’s shares closed last Wednesday at $19.71.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 7.5% and a 43.1% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Urogen Pharma with a $46.33 average price target.
Urogen Pharma’s market cap is currently $408.7M and has a P/E ratio of -3.10. The company has a Price to Book ratio of 4.24.